Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Shakya, Nabin Bhakta; Jha, Sagar Mani; Dangol, Anil Kumar Singh; Shakya, Sanil; Shah, Anshul

doi:10.3126/mjsbh.v11i1.7763

Cited by 10 publications

(14 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Observations similar to our study were made in Nepal by Shakya et al which showed that itraconazole has high cure rate and less failure rate without side effects in comparision to terbinafine. 10 Also, in contrast to our study where we found itraconazole to be most efficacious drug, a study by Sultana et al in Bangladesh found more number of patients to be resistant to itraconazole, followed by fluconazole. Least drug resistance was found with terbinafine.…”

Section: Fluconazolecontrasting

confidence: 99%

A comparative study of efficacy of oral itraconazole, terbinafine and fluconazole: a clinical trial

Koregol

Naik

Hosthota³

et al. 2021

Int J Res Dermatol

View full text Add to dashboard Cite

Background: Keeping in view the rising number of cases of dermatophyte infections and also poor response to topical drugs, this study was conducted with the intention to arrive at a conclusion regarding the best available systemic drug.Methods: A total of 270 patients were selected for the study. 90 patients were assigned to each group under itraconazole, terbinafine & fluconazole.Results: It was found that itraconazole was the most effective drug which led to a considerable decrease in erythema, peripheral spread, scaling and spread to other body sites. Next drug to be the most effective was terbinafine, which was followed by fluconazole.Conclusions: We finally arrived at a conclusion that itraconazole is the most effective drug for all types of superficial fungal infections. It was followed by terbinafine & fluconazole in terms of drug effectiveness. Hence in this study we advocate the use of itraconazole as first line of drug in all patients of tinea infections.

show abstract

Section: Fluconazolecontrasting

confidence: 99%

A comparative study of efficacy of oral itraconazole, terbinafine and fluconazole: a clinical trial

Koregol

Naik

Hosthota³

et al. 2021

Int J Res Dermatol

View full text Add to dashboard Cite

show abstract

“…This is similar to an earlier study in patients of tinea cruris who also found itraconazole to have higher cure rates as compared to terbinafine. [9] Although studies on toenail onychomycosis have found terbinafine to be more effective than itraconazole,[16] we found the reverse to be true for tinea corporis and tinea cruris. Both the drugs have a similar pharmacokinetic profile.…”

Section: Discussionmentioning

confidence: 60%

“…It has shown good results in the treatment of dermatophytosis at doses of 100 mg once a day for 2 weeks and with 200 mg once a day for 7 days. [910] Because of frequent relapses at short intervals, some physicians have used it in doses of 200 mg once a day for prolonged periods. [1112]…”

Section: Introductionmentioning

confidence: 99%

Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin – A prospective, randomized comparative study

et al. 2019

View full text Add to dashboard Cite

OBJECTIVES: Dermatophytic infections are the common fungal infections aggravated by hot and humid climate. Terbinafine and itraconazole are commonly used oral antifungal agents for the same. However, resistance to these drugs is being seen increasingly when used in the conventional doses and duration. Therefore, this study was designed to compare the efficacy of terbinafine and itraconazole in increased dosages and duration in the treatment of tinea corporis and tinea cruris. MATERIALS AND METHODS: In this randomized comparative study, patients of tinea cruris and tinea corporis were randomly divided into two groups of 160 each and were given oral terbinafine (Group I) and oral itraconazole (Group II) for 4 weeks. The scores and percentage change in scores of pruritus, scaling, and erythema were evaluated at 2 and 4 weeks. RESULTS: At the end of week 4, mycological cure was seen in 91.8% after 4 weeks in the itraconazole group as compared to 74.3% of patients in the terbinafine group. There was a significant improvement in percentage change in pruritus, scaling, and erythema in both the groups from 0 to 4 weeks. On comparing groups, the percentage change was significantly different in scaling from 0 to 2 weeks (5.4 vs. −4.8) and 2–4 weeks (16.7 vs. 29.6) between Group I and Group II, respectively. Clinical global improvement was better with itraconazole. Mild adverse effects such as gastrointestinal upset, headache, and taste disturbances were observed which were comparable in both the groups. CONCLUSIONS: Itraconazole and terbinafine seem to be equally effective and safe in the treatment of tinea cruris and tinea corporis.

show abstract

“…It has shown good results in the treatment of dermatophytosis at doses of 100 mg once a day for two weeks and with 200 mg once a day for seven days. 16,17 But due to frequent relapses at short intervals, some physicians in India have used it in doses of 200 mg once a day for prolonged periods. 7,18 High dose of itraconazole may not be beneficial due to non-linear pharmacokinetic property.…”

Section: Introductionmentioning

confidence: 99%

“…Some recent trials compared the efficacy of terbinafine and itraconazole but in standard doses and duration. 16,21 Recently, a combination of itraconazole and terbinafine has also been studied 22 suggesting need of either high dose or combined dose of different systemic antifungals in current settings in India. But there is no any study comparing high dose of terbinafine against standard dose of itraconazole.…”

Section: Introductionmentioning

confidence: 99%

Comparative evaluation of efficacy and safety of terbinafine and itraconazole in the management of tinea corporis et cruris

Dhoot¹,

Shah²,

Shah³

et al. 2020

IJCED

View full text Add to dashboard Cite

The management of dermatophytosis is challenging in India and there are reports of using systemic antifungals at higher doses. But there are multiple reports of increased treatment failures with terbinafine at standard dosage as well, hence we conducted this study to compare efficacy and safety of high dose of terbinafine with itraconazole at standard dose. Topical ciclopirox olamine was used in both arms.This was randomized, open label, comparative study where 80 patients with tinea corporis et cruris infection were included. Patients were either prescribed terbinafine 250mg twice a day or itraconazole 100mg twice a day for 4 weeks. Efficacy was assessed based on complete, clinical and mycological cure rate. Safety was assessed by evaluating adverse events and monitoring liver function of patients.Total 76 patients completed the study with 38 in each group. 81.5% patients achieved complete cure in terbinafine group compared to 76.31% patients in itraconazole group. At the end of six weeks, there was a statistically significant improvement (p value<0.05) in the total symptom score (erythema, scaling, and pruritus) in Group I as well as in Group II compared to baseline. None of the patients showed any significant side effect in both Itraconazole and Terbinafine groups. No changes in liver function were observed in both the groups. This study shows that the high dose of terbinafine in combination with topical ciclopirox is effective and safe in management of tinea corporis et cruris.

show abstract

Efficacy of Itraconazole Versus Terbinafine for the Treatment of Tineacruris.

Cited by 10 publications

References 10 publications

A comparative study of efficacy of oral itraconazole, terbinafine and fluconazole: a clinical trial

A comparative study of efficacy of oral itraconazole, terbinafine and fluconazole: a clinical trial

Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin – A prospective, randomized comparative study

Comparative evaluation of efficacy and safety of terbinafine and itraconazole in the management of tinea corporis et cruris

Contact Info

Product

Resources

About